Myocardial infarction and heart failure are leading causes of the mortality worldwide. The NHP model of myocardial ischemia/reperfusion injury is very unique for the evaluation of new therapeutics (particularly protein products and gene therapies) to clinical application devoid of inter-species variations. 

KBI has various models of ischemic-reperfusion by blocking and releasing the left anterior descending (LAD) artery. The ischemia and reperfusion injury is monitored by the ST elevation (STEMI) in ECG, plasma levels of creatine kinase (CK) and lactate dehydrogenase (LDH), and can be further examined by gross morphology and histopathology.